Additionally, multiple randomized clinical trials using checkpoint inhibitors related to CTLA4, administered alone or in combination with other treatment modalities for NSCLC, are ongoing, and are expected to achieve better survival outcomes with acceptable toxicity levels (Hodi et al., 2010; Hellmann et al., 2018). The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.